Search for a command to run...
No recent news available for this stock.
Conference call summary is not available for this stock.
Themis Medicare Ltd. exhibits moderate growth and profitability metrics compared to its peers in the Pharmaceuticals & Drugs sector. While it is not the highest performer in any category, it maintains a solid position with low debt and reasonable EBITDA margins, suggesting stability. However, several peers outperform it in growth and return metrics, indicating competitive pressure.
Highest revenue growth YoY at 18.12% and strong profitability metrics.
Best overall balance of growth, profitability, and low valuation metrics.
Strong profitability with a ROE of 21.76% and attractive PEG of 0.19.